© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Latest Conference Articles
Health Care Workers Likely to Recommend COVID-19 Vaccine to Patients Based on Safety Messaging, Survey Finds
September 30th 2021
Survey authors said findings merit further research into how to increase health care workers' confidence in discussing and recommending COVID-19 vaccines with patients.
Obesity May Put Children Hospitalized with COVID-19 at Higher Risk for Severe Disease, Suggests New Study
September 29th 2021
IDWeek 2021: Obesity prevention and vaccination efforts may help prevent COVID-19-related morbidity in pediatric COVID-19 patients with obesity, noted authors of a new study.
IDWeek 2021: C diff Clinical Outcomes Unchanged after 2017 IDSA Guideline Update
September 29th 2021
IDWeek 2021: Use of vancomycin vs metronidazole increased after the 2017 IDSA recommendation but CDI recurrence rates increased slightly, investigators report.
HCV Cure is Possible in Young Drug Users, Suggests New Research Being Presented at IDWeek 2021
September 28th 2021
IDWeek 2021: Young people who inject drugs can be cured of hepatitis C virus infection, according to 2 new studies.
Remdesivir May Significantly Reduce Risk of Hospitalization in High-risk COVID-19 Patients, Suggests New Study
September 23rd 2021
Findings from a phase 3 clinical trial showed remdesivir reduced the risk of COVID-19-related hospitalizations by 87% in high-risk patients, the drug's manufacturer announced.
At ADA 2021, John Buse, MD, PhD, says US Must Focus on Control of Obesity, Other T2D Risk Factors
June 30th 2021
Diabetes investigator John Buse, MD, PhD, says laser focus on reducing T2D risk factors is equally as important as using the next right drug against the disease.
Inside GRADE: Exec Committee Member John Buse, MD, PhD, Toplines Study Results, Calls for More Head-to-Head Research
June 30th 2021
Dr Buse’s in-depth review of the GRADE study is followed by a discussion of the keen need for more comparative research and the many new questions the results have raised about optimal T2D therapy.
ADA 2021: Baseline Insulin Use May not Impact Benefits of Finerenone in Patients with CKD, T2D
June 29th 2021
ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.
GLP-1 RA, Insulin More Effective Second-line vs Sulfonylurea, DPP-4 Inhibitor for T2D
June 29th 2021
Preliminary GRADE study results showed that liraglutide and insulin glargine added to metformin maintained A1c level in target range longer than glimepiride or sitagliptin.
ADA 2021: Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD
June 29th 2021
ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.